TY - EJOU AU - Ganbat, Dariimaa AU - Jugder, Bat-Erdene AU - Ganbat, Lkhamaa AU - Tomoeda, Miki AU - Dungubat, Erdenetsogt AU - Miyegombo, Ambaga AU - Garmaa, Gantsetseg AU - Takahashi, Yoshihisa AU - Fukuzawa, Ryuji AU - Mori, Ichiro AU - Shiomi, Takayuki AU - Nakata, Akinori AU - Tomita, Yasuhiko TI - Use of the Naphthoquinone YM155 (Sepantronium Bromide) in the Treatment of Cancer: A Systematic Review and Meta-Synthesis T2 - Oncologie PY - 2022 VL - 24 IS - 2 SN - 1765-2839 AB - Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels. Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical outcomes and pharmacological parameters, and further performed subgroup analysis based on tumor type and treatment regimen. Our comprehensive analysis, which included patients of many ethnicities, demonstrated that YM155 was effective as a monotherapy or combination therapy. Clinical benefits, including regression and/or stabilization of tumor progression and prolonged survival, were observed within a reasonable time after treatment initiation, and YM155 displayed good synergistic effects with combination drugs. YM155 appears to be effective against a wide range of tumor types and has an acceptable safety profile, with the main toxicities being decreased blood cell counts; fatigue/weakness; renal, hepatic, and/or cardiac issues; and electrolyte disturbance. KW - YM155 (sepantronium bromide); systematic review; safety; anticancer effect; meta-synthesis; Naphthoquinone DO - 10.32604/oncologie.2022.022299